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osting by EAbstract Rett syndrome (RTT) is a progressive neurodevelopmental disorder that affects mainly
females comprising one of the most common causes of mental retardation in females. Mutations in
the X-linked MECP2 gene have been identiﬁed to be the major cause for RTT. This study repre-
sents one of the limited MECP2 molecular analyses done on Egyptian patients with RTT, in which
direct sequencing of MECP2 coding region in 10 female Egyptian patients provisionally diagnosed
to have RTT was carried out. Four different pathogenic mutations were identiﬁed in four patients;
three missense (C380T, C397T and C916T) and one nonsense (C382T). The four mutations, Cﬁ T
transitions, were located in exon four. Patients with MECP2 mutation showed the clinical course ofell Research Lab, National
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Rett syndrome (RTT) (MIM 312750) is an X-linked dominant
[1] neurodevelopmental disorder that affects mainly females [2]
with a prevalence estimated to be 1 in each 10,000–15,000 fe-
male births [3,4]. RTT was ﬁrst described by the Austrian pedi-
atrician Andreas Rett in 1966 [5], however his article attracted
little attention because it appeared in a German language jour-
nal that was not widely read out in Europe. In 1983, the Swed-
ish researcher Bengt Hagberg published a report of 35 cases
from Sweden, France and Portugal in Annals of Neurology
which led to the worldwide recognition of RTT [2].
Girls with typical RTT are essentially characterized by nor-
mal birth and apparently normal psychomotor development
during the ﬁrst 6–18 months of life. The affected females then
enter a short period of developmental stagnation followed by a
period of rapid regression, during which they lose acquired
speech and purposeful hand use, and showed acquired micro-
cephaly, autistic features, and walking problems. The hallmark
of the disease is the loss of purposeful hand use and its replace-
ment with repetitive stereotyped hand movements. Secondary
characteristics may include seizures, breathing abnormalities,
vasomotor disturbances, skeletal deformities and abnormal
muscle tone. By puberty, most patients stabilize and some
may recover some skills [6]. In addition to the classic form of
RTT, ﬁve atypical variants have been delineated on the basis
of clinical criteria. Each variant lacks some of the necessary
criteria of the classic form and can be milder or more severe.
The milder variants are the preserved speech, the forme fruste
and the late regression variants. The more severe forms are the
early-seizure-onset and the congenital variants [7]. Most fe-
males with RTT survive to the middle age [8].
Approximately 99.5% of RTT cases are sporadic. In the
few familial cases, the mutation is either present in the asymp-
tomatic mother or due to germline mosacisim in one of the
parents. The lack of phenotypic expression in the asymptom-
atic carrier mothers was shown to correlate with skewed X
chromosome inactivation (XCI) pattern [9].
Numerous reports indicated that mutations in the coding se-
quence of MECP2 gene (the gene that encodes methyl-CpG-
binding protein2, MeCP2) (MIM 300005) are the major cause
of most typical cases of RTT. MECP2 mutations were also
found, but less frequently, in girls with atypical forms [10].
MECP2 mutations were identiﬁed throughout the coding re-
gion of the gene including missense mutations, nonsense muta-
tions, small insertions or deletions, splicing mutations, and
large rearrangements (duplications or complex deletions) [11].
MECP2 is a four-exon gene located at the terminal end of
the long arm of X chromosome (Xq28) [12]. It is ubiquitously
expressed [13], however its high levels have been detected in the
brain [14] where it is involved in the maturation of neurons
[15]. Loss of MeCP2 functions in the brain leads to reduction
in neuronal size and in the length and number of dendrites [16]
and subsequently causing deﬁcits in synaptic formation and/ortransmission [17]. The assumption that MeCP2 is mainly re-
quired for the maturation of existing neurons rather than the
development of new neurons from precursor cells may explain
the delayed onset of RTT [18].
MeCP2 was thought to be a transcriptional repressor that
prevents unscheduled transcription of other genes by binding
to methylated CG dinucleotides in some gene promoters and
recruiting histone deacetylases (HDACs), ultimately causing
chromatin compaction and gene silencing [19]. MECP2 muta-
tions result in apparent expression of other genes leading to
RTT progression [20]. So far several genes associated with
brain development were reported as MeCP2 targets such as
brain-derived neurotrophic factor (BDNF) [21], DLX5 [22],
glucocorticoid-regulated genes [23], the four ID genes [24], a
transmembrane modulator of Na+, K+-ATPase activity
(FXYD1) [25], and protocadherins PCDHB1 and PCDH7
[26]. MeCP2 role may be more complex than it was thought,
MeCP2 was suggested to be implicated in the formation of
chromatin loop at the repressed loci [22], regulation of RNA
splicing [27] and transcriptional activation of some genes [28].
MeCP2 contains two major functional domains; methyl-
CpG-binding domain (MBD) [29] and transcriptional repres-
sion domain (TRD) [19,30]. Within the TRD, there is a nuclear
localization signal (NLS) that mediates the transport of the
protein into the nucleus [31].
This study has been carried out at the Human Stem Cell
Lab, CEAS, and core genomic lab - NRC. PCR and direct
sequencing were used to analyze the coding sequence of
MECP2 in Egyptian patients with RTT.
2. Materials and methods
2.1. Subjects
Ten female patients, included in this study, were provisionally
diagnosed to have RTT. They were identiﬁed at the Out-pa-
tients Clinic of the Clinical Human Genetics Department, Na-
tional Research Centre.
2.2. Mutation analysis
DNA of RTT patients was extracted from peripheral blood
leukocytes using the salting out protocol [32]. The three coding
exons (exons 1, 3 and 4) and the ﬂanking intronic sequences of
MECP2 were ampliﬁed in overlapping fragments. Primers
used for exons 3 and 4 were previously reported by Bienvenu
et al. [33]. We have designed other set of primers to generate
shorter fragments for sequencing.
PCR was performed in a total volume of 30 ll containing
100 ng of genomic DNA, 30 pmol of each primer, 200 lM of
dATP, dCTP, dTTp and dGTP, 1.5 lMMgCl2, 1X Taq buffer
and 2.5 U Taq polymerase (Fermentas, EU). The PCR prod-
ucts were puriﬁed using the PCR puriﬁcation kit (Qiagen, Hil-
den, Germany) and sequenced with Big dye Terminator V3.1
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and ABI prism 310 Genetic Analyzer (Applied Biosystems,
California, USA).
2.3. X-chromosome inactivation analysis
Patients with MECP2 mutation were tested for X chromosome
inactivation pattern using the same protocol described previ-
ously by Calvo et al. [34].
3. Results
All patients were, basically, autistic, microcephalic and showed
repetitive stereotypic hand movements. Therefore, they were
referred with a provestional diagnosis of Rett syndrome and
requesting MECP2 molecular analysis. The Clinical criteria of
the studied patients are summarized in Table 1 and the score
achieved by each patient according to RTT checklist described
by Huppke et al. [35] is showed in Table 2. Molecular analysis
of MECP2 gene in those patients revealed four different disease
causingmutations in four unrelated patients (Table 3). The iden-
tiﬁed mutations located in exon 4; three were within the MBD
and one in the TRD (Fig. 1). One novel silent mutation in exon
3 (C210T) was also reported in patient 1, in whom a pathogenic
mutation (P127L)was detected (Fig. 2). Analysis ofXCI pattern
in patients with MECP2 mutations was informative in all of
them and revealed random pattern in three patients and skewed
pattern in only one patient (Fig. 3). Sequence analysis of
MECP2 mutations in mothers of female patients with positive
MECP2mutation showed that they were negative for the muta-
tion detected in their daughters.
4. Discussion
RTT is one of the most common causes of mental retardation
in females with a prevalence estimated to be 1 in each
10,000:15,000 female births [3,4]. MECP2 gene mutations were
identiﬁed to be the major cause of RTT. They are found in 80–
90% of classic RTT patients and in 20–40% of patients with
RTT variants [37]. Detection of the underlying cause in RTT
patients will conﬁrm the diagnosis, helping clinicians to man-
age their patients better and to offer precise counseling.
Furthermore, it may provide insight regarding genotype-phe-
notype correlation.
This study represents one of the limited molecular analyses
of MECP2 gene in Egyptian patients with RTT. A previous re-
port from our group was published in 2007 [38]. Direct
sequencing of the MECP2 coding sequence of 10 female pa-
tients that included in this study revealed four different patho-
genic mutations in four unrelated patients; three missense and
one non sense. Generally, MECP2 mutations were detected in
about 80% of RTT patients [39,40]. However, some previous
studies showed relatively low rate of mutation detection and
this mainly might depend on the clinical selection of the stud-
ied patients. Xiang et al. [41] screened the MECP2 gene for
mutations by direct sequencing in 68 RTT cases and only a to-
tal of 27 patients (40%) were found to have mutations in the
MECP2 gene. Raizis et al. [42] analyzed the MECP2 coding re-
gion by both direct automated DNA sequencing and MLPA in
74 patients with global developmental delay and mental retar-
dation from New Zealand. The MeCP2 mutations among this
selected group were only 20%.The checklist for RTT described by Huppke et al. [35] seems
to be effective in giving a better screening tool. According to this
checklist, molecular analysis should be carried out only in pa-
tients achieving a score of 8 or more out of 12. In this study, pa-
tients with detectedMECP2mutations had a score of 10 at least.
The studied patients were under continuous clinical follow
up and it has been reported that the consanguineous parents of
P7 have got recently another affected microcephalic daughter.
In association with that, our index case P7 may be a case of
autosomal recessive microcephalic disorder rather than RTT.
As RTT is an X-linked disorder, the X chromosome inacti-
vation (XCI) pattern will have a signiﬁcant impact on the
clinical phenotype in patients with skewed XCI pattern where
the disease severity decreases if the X chromosome with the
normal gene is activated in majority of cells and vice versa.
Analysis of the XCI pattern in our patients with positive
MECP2 mutation revealed skewed pattern of inactivation in
only one patient (P4) that couldn’t walk, speak and use hand.
Other studies reported that R306C, the same mutation de-
tected in this patient, might be generally associated with a rel-
atively milder phenotype [43–46]. Therefore it can be
postulated that in this patient, the XCI pattern favored activa-
tion of the X chromosome carrying the mutant allele in a large
number of cells.
Generally, it was indicated that random XCI was the main
pattern reported in RTT cases [47] denoting that XCI pattern
is not a main modiﬁcation factor on clinical phenotypes of
RTT.
The three missense mutations identiﬁed in this study were
P127L, R133C and R306C. P127L and R133C are located in
the MBD, but R306C in the TRD. In previous reports,
P127L showed low recurrence rate. To the best of our knowl-
edge it was reported only 4 times before, the ﬁrst report in 2001
in a patient with PSV [48]. Then, it was later identiﬁed in only 3
patients; 2 patients in a French study [49] and one patient in
another study in China [9]. In contrast, R133C and R306C
are of the most commonly occurring MECP2 mutations
accounting for about 5.4% and 6.4% of RTT patients respec-
tively [11]. Generally, it has been shown that the missense
mutations were associated with milder phenotypes than trun-
cating mutations [43,50]. Ham et al. [51] revised the mutations
detected in 45 patients reported in 4 studies [52–55] with the
milder RTT variants (PSV and forme fruste). They found that
those patients mainly had carboxyl-terminal truncations and
eight missense mutations. Of these missense mutations were
P127L, R133C and R306C. The other ﬁve missense mutations
identiﬁed were E10Q, T158 M, T158A, R168X and P302A.
Hence, they inferred that a patient with a mild phenotype is
likely to disclose either a carboxyl-terminal truncation or one
of these missense mutations [51]. In our study, the mutations
P127L, R133C and R306C were associated with classical
course of RTT rather than a milder variant (Patients 1, 3
and 4).
Leonard et al., 2003 studied 24 patients having R133C to
examine the phenotype associated with this mutation speciﬁ-
cally and they found that the phenotype of a patient with
R133C mutation is overall milder with better ambulation,
hand use and a greater likelihood of being able to use speech
[56]. Subsequently, Neul et al. [57] studied a large cohort of
245 patients with typical RTT. They identiﬁed R133C in 12 pa-
tients and reported that it was associated with relatively mild
phenotype. Most patients with R133C preserved some hand
Table 1 The clinical phenotypes of studied female patients.
Patient
number
and initial
Age at
regression
Ability to
walk
Ability to
speak
Ability to
use hand
Stereotypical
hand movements
Postnatal
microcephaly
Seizures Behavioral
abnormality
Muscle tone and
reﬂexes
P1-WA At 1 year Walked with
gait ataxia
Lost No hand use Clapping
movements
47 cm (SD 2.7) at 4.5 years Mild generalized
epilepsy
Autistic features,
swinging of moods,
grinding
Hypotonia, brisk
reﬂexes
P2-NW At 1.5 years Never walked No speech No hand use Washing
movements
47 cm (SD 3.6) at 8 years Not reported
in her ﬁle
Autistic features,
pulls her clothes,
grinding
Hypotonia, brisk
reﬂexes
P3-NE At 1.5 years Weak walking Lost Impaired
hand use
Abnormal hand
movements
48.5 cm (SD 2.6) at 9 years Frequent
seizures
Autistic features Hypotonia,
hyperreﬂexia
P4-AH At 9 months No walking Lost Lost Clapping &
wringing
movements
44 cm (SD 3.8) at 2.5 years Generalized
epilepsy
Autistic features,
bruxism
Hypotonia,
hyporeﬂexia,
spasticity
P5- SW Not reported Started walking
late (at 3 years)
No speech No hand use Flapping
movements
44.7 cm (SD 4.7) at 4 years, Not reported
in her ﬁle
Autistic features
Laughing spells,
babbling, grinding
Hypotonia,
hyperreﬂexia
P6- SR At 14 months Started walking
late (at 2 years)
No speech Lost Clapping
movements
45.8 cm (SD 2.5) at 3 years No seizures Autistic features,
babbling, spitting
Not reported
P7- SA At early life No walking No speech No hand use Abnormal
hand movements
43.5 cm (SD 4) at 4 years Not reported
in her ﬁle
Autistic features Hypotonia,
brisk reﬂexes
P8- NM At 8 months Impaired walking Impaired
speech
Impaired
hand use
Abnormal
hand movements
45 cm (SD 3.5) at 6 years Generalized and
tonic-clonic, epilepsy
Autistic features, Not reported
P9- WS At 7 months Impaired walking No speech Impaired
hand use
Abnormal
hand movements
46 cm (SD 2) at 3 years Epileptic ﬁts Autistic features,
babbling
Hypotonia,
brisk reﬂexes
P10- MS At 9 months Walked with aid No speech No hand use Clapping &
wringing movements
45 cm at 3.5 years Not reported in
her ﬁle
Autistic features Hypotonia, reﬂexes
impaired walking, speech, hand use: skill ability is affected in a certain way.
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Table 2 RTT checklist for studied female patients (the checklist is quoted from Huppke et al. [35]).
Clinical criterion Patient
Patients with MECP2 mutation Patients without MECP2 mutation
P1-
WA
P2-
NW
P3-
NE
P4-
AH
P5-
SW
P6-
SR
P7-
SA
P8-
NM
P9-
WS
P10-
MS
Normal prenatal and perinatal
period
1 1 1 1 1 1 1 1 1 1
Normal psychomotor
development during the ﬁrst
6 months
1 1 1 1 n.d. 1 0 1 1 1
Normal head circumference at
birth
Not measured at birth, however the parents didn’t notice relatively small head circumference at
birth
Deceleration of head growth 1 1 1 1 1 1 1 1 1 1
Hand skills (1 if never, 2 if lost) 1 1 1 1 n.d. 2 n.d. n.d. n.d. 1
Stereotypic hand movements 1 1 1 1 1 1 1 1 1 1
Communication dysfunction and
social withdraw
1 1 1 1 1 1 1 1 1 1
Acquired language (1 if never, 2 if
lost)
2 1 2 1 n.d. 1 n.d. n.d. 1 1
Severe psychomotor retardation 1 1 1 1 n.d. 1 0 1 1 1
Impaired or absent locomotion 1 1 1 1 n.d. n.d. n.d. n.d. n.d. 1
Score P11 P10 P11 P10 P4 P9 P4 P9 P7 P10
n.d.: Not documented.
                  C380T  
 C397T                            C916T 
                   C382T 
TRD MBD 
                   1     26                              235      377    485                              625             930                                1461 
ex 4 ex 3 
Figure 1 Distribution of the identiﬁed pathogenic mutations along the coding sequence of MECP2 gene. Diagramatic illustration of
MECP2 gene and its function domains (this ﬁgure was adapted from Dragich et al. [36]). Nucleotides are numbered from the ﬁrst
nucleotide of the start ATG codon of the b isoform. The coding sequences for the MBD and TRD are indicated in yellow and red
respectively. The NLS is hatched. Missense mutations are shown above and nonsense mutation below the sequence.
Table 3 Mutations of the MECP2 gene detected in the studied RTT patients.
Patient Nucleotide change Amino acid change Mutation type Domain Exon X inactivation pattern
P1-WA C380T P127L Missense MBD Exon 4 Random
*C210T S70 Silent – Exon 2
P2-NW C382T Q128X Nonsense MBD Exon 4 Random
P3-NE C397T R133C Missense MBD Exon 4 Random
P4-AH C916T R306C Missense TRD Exon 4 Non-random
* this sequence variation has not been reported before.
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and a signiﬁcant proportion spoke words (50%). On the other
hand, R306C was identiﬁed in another 21 patients and it was
shown that a large set of patients with R306C could walk
(67%) and retained some hand use (52%), but very few were
able to use words. In our study, both patients with R133C
and R306C showed lack of their ability to walk and use their
hands, however, they showed different ambulation ability.
While the patient with R133C could walk alone, the one withR306C didn’t walk. In the latter, this may be attributed to the
skewed X chromosomes inactivation identiﬁed in this patient.
Furthermore, it has been demonstrated that patients with
R133C and R306C tend be associated with heightened anxiety
and fear [58]. Several studies demonstrated that R133C
strongly impaired MeCP2 binding to methylated DNA [59–
61]. On the other hand, R306C probably affects the ability
of MeCP2 to recruit corepressor complexes impairing its func-
tion in the process of transcriptional repression [62].
Figure 2 Electropherograms of DNA sequencing for MECP2
mutations identiﬁed in RTT patients in this study. Substituted
nucleotides are indicated by arrows and substituted amino acids
are underlined. All sequences are in the sense orientation.
Figure 2 (continued)
24 M.S. Zaki et al.As P127L shows low recurrence rate, little information was
reported about its associated clinical phenotype and its func-
tional consequences on MeCP2. Our patient with this muta-
tion is similar to that having R133C. She was also able to
walk, but couldn’t speak or use hands.
Q128X, the nonsense mutation identiﬁed in our study is
located in the MBD and presenting one of the few nonsensemutations identiﬁed in this domain. Most mutations reported
in this domain were missense, however the nonsense muta-
tions were clustered in the TRD domain and the region
between the MBD and the TRD (the inter-domain (ID)
region) [49,63]. Q128X has very low recurrence rate. To our
knowledge, it was reported in only one patient in the study
of Philippe et al., 2006, in which no clinical data were
documented for the affected individual [49]. Previous reports
documenting that truncating (nonsense and frameshift) muta-
tions, in general, are associated with a more severe disease
phenotype than missense mutations [43,50]. However, a
milder disease was noted in patients with truncating muta-
tions within or downstream of the TRD as compared with
those who have truncating mutations upstream of the
TRD. Dragich et al. [36] explained this difference in truncat-
ing mutations outcome as a consequence of their gene
location. Huppke et al. [52] found that mutations lead to
either a complete or partial truncation of the region coding
for the nuclear localization signal (NLS) is associated with
a more severe phenotype than other truncating mutations.
They suggested that mutations leading to a truncation of
the NLS produce proteins that will remain in the cytoplasm
with more loss of protein function. However missense muta-
Figure 3 Analysis of X chromosome inactivation (XCI) pattern
using the androgen receptor methylation assay. Ethidium bromide
stained agarose gel electrophoresis for PCR products of patients
with identiﬁed MECP2 mutations. Aliquot of DNA of peripheral
blood leukocyte from each patient was used directly as a template
(- lanes) and another aliquot was digested with HpaII prior to
PCR ampliﬁcation (+ lanes). All analyzed patients are informa-
tive i.e, have alleles with different size repeats. Patient 4 is the only
one that had non random. R: random - NR: non random.
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residual protein function. Our patient with Q128X showed
a classical phenotype with normal development at the ﬁrst
months of life and no seizures in early life denoting that
she is not a case of congenital or early onset seizures RTT
variant. However, she assessed a relatively high combined
severity score for the abilities of hand use, speech and walk-
ing. She was unable to walk, speak or use hand. In accor-
dance with Amir et al. [64] who found that patients with
truncating mutations have a higher incidence of the awake
respiratory dysfunction, this girl showed abnormal breathing.
Additionally, this patient exhibited other minor criteria of
RTT such as vasomotor instability, constipation, hypotonia
and brisk reﬂexes.
All detected mutations including the silent one are Cﬁ T
transitions. However in P127L and Q128X, the transitioned
cytosines are not at CpG dinucleotides. Hence, these 2 muta-
tions may be resulted from transitions of unmethylated cyto-
sines which are less amenable for chemical modiﬁcation and
this may explain the relatively low recurrence rate of both of
them.
Although Approximately 99.5% of RTT mutations arise
de novo, mothers may rarely carry the mutation without
manifesting the phenotypic expression due to skewed XCI.
We investigated the mutation presence in mothers of patients
with positive MECP2 from whom DNA could be obtained
indicating that no mutation was present in the maternal
DNA.
RTT occurs in all ethnic groups across the world [65]. How-
ever, no discrimination in the spectrum and the frequency of
MECP2 mutations could be revealed among the different pop-
ulations. This can be explained as most MECP2 mutations
originate de novo [66]. Molecular analysis of MECP2 gene in
7 Tunisian patients with RTT identiﬁed T158M mutation in
4 patients (more than 50%) [62], however this mutation was
not detected in our studied patients.5. Conclusion and recommendations
This is one of the limited genetic studies of Rett syndrome
in Egypt. The relatively low observed frequency of MECP2
mutations may reﬂect a wide spectrum of mental disability
disorders. However, analysis of large rearrangements
should be carried out in patients without MECP2 mutation
to reduce the risk of false negatives and to increase the
sensitivity.
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